Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma

Trial Profile

A dose-ranging study of fluticasone furoate (FF) inhalation powder in children aged 5-11 years with asthma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluticasone furoate (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Registrational; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK
  • Most Recent Events

    • 12 Sep 2023 Results from (HZA102942,HZA112776 and HZA112777) and two Phase 2b(HZA106855 and HZA106853) assessing compare model-predicted steady-state maximumplasma concentrations (Cmax) and overall systemicexposure (AUC0-24) of FF and VI in pediatric Japaneseand non-Japanese population subgroups presented at the 2023 American College of Clinical Pharmacology Annual Meeting
    • 21 May 2018 Results presented in the GlaxoSmithKline media release.
    • 21 May 2018 According to a GlaxoSmithKline media release, based on the data from this trial GlaxoSmithKline has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta (fluticasone furoate) as maintenance treatment of asthma as prophylactic therapy in children aged 5 to 11 years (inclusive).
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top